Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / COM
-
Number of holders
-
72
-
Total 13F shares, excl. options
-
17.7M
-
Shares change
-
+2.71M
-
Total reported value, excl. options
-
$274M
-
Value change
-
+$44.3M
-
Number of buys
-
42
-
Number of sells
-
-28
-
Price
-
$15.48
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q1 2020
79 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q1 2020.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 72 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.7M shares
.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (2.8M shares), Consonance Capital Management LP (2.24M shares), HILLHOUSE CAPITAL ADVISORS, LTD. (1.9M shares), ArrowMark Colorado Holdings LLC (1.27M shares), VANGUARD GROUP INC (1.2M shares), BlackRock Inc. (933K shares), Sofinnova Investments, Inc. (923K shares), Vivo Capital, LLC (759K shares), AMERIPRISE FINANCIAL INC (651K shares), and CITADEL ADVISORS LLC (522K shares).
This table shows the top 72 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.